$IMMP has been discussed by 2 distinct FinTwit voices over the past 12 months, generating 5 mentions between March 13 and April 20, 2026. @jacobplieth (Jacob Plieth) has been the most active voice, contributing 4 mentions, while @acinvestorblog (Antonio Costa) posted 1 mention. The biotech category dominated discussion of Immutep Ltd during this period.

The earliest mention of $IMMP appeared on March 13, 2026, when @jacobplieth noted that the company's choice to pursue lung cancer over head and neck cancer in phase 3 trials, though strategically sound, still resulted in trial failure and a significant stock decline. More recently, on April 20, 2026, @acinvestorblog shared a technical observation regarding the stock's price level near 67 cents.